Skip to content
lifestyle.toptraveltrends.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Evaxion
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
October 23, 2026
Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
October 19, 2026
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
October 2, 2026
Evaxion applies its AI-Immunology™ platform in autoimmune diseases
September 14, 2026
Evaxion announces business update and second quarter 2026 financial results
August 20, 2026
Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program
August 17, 2026
Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026
August 14, 2026
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
May 12, 2026
Evaxion announces business update and first quarter 2026 financial results
May 7, 2026
Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026
May 4, 2026
1
2
Next Page
→